Simulations Plus Releases DDDPlus Version 3.0

Major Update to One-of-a-Kind Software Increases Value to Formulation Scientists
LANCASTER, Calif.--(Business Wire)--
Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of simulation and
modeling software to the pharmaceutical industry, announces the release of
DDDPlus 3.0, a major update to its unique software that simulates in vitro
dissolution experiments to assist pharmaceutical formulation scientists in the
design of new dosage forms and new experimental conditions.

Dr. John Chung, product manager for DDDPlus and a member of the Simulation
Technologies team at Simulations Plus, said: "This new version of DDDPlus is the
result of many months of work to produce a major redesign of the underlying
architecture and user interface of the program, to add to the simulation
accuracy of certain aspects of the program, as well as add a number of new
capabilities requested by our users in the U.S., Europe, and Japan. Enhancements
to this new version include a new solubility-vs-pH model that more accurately
calculates the solubilities of both the active drug and the excipients in a
dosage form as the pH of the dissolution medium (the fluid in the experiment
container) is changed. We have also made the user interface identical to our
flagship GastroPlus software in every way practical, so that users of both
programs see the same interface for the same functions. We`ve added a new open
loop simulation for the USP 4 flow-through method, in addition to the previous
closed loop simulation. We expanded the built-in library of excipients
(ingredients other than the drug itself). As a result of user requests, we also
expanded the built-in list of buffer solutions used in in vitro dissolution
experiments to include buffers from the Japanese Pharmacopeia and additional
acetate buffers from the U.S. Pharmacopeia."

Walt Woltosz, chairman and chief executive officer of Simulations Plus added:
"DDDPlus remains the only program of its kind in the world today. DDDPlus saves
time and money. It`s that simple. Rather than an iterative process of
design-experiment-design-experiment, DDDPlus enables formulation scientists to
run a single experiment to calibrate the model for a particular type of dosage
form, and then to use simulations to investigate which changes in the
formulation or in the experiment will achieve the desired results. We decided
five years ago that a program like this was a good investment for organic
growth. Version 1.0 was released in February 2005; however, adoption was slow
for the first couple of years because formulation scientists were not accustomed
to the idea of using simulations for in vitro experiments. Since then the number
of users has increased steadily, and the adoption rate has accelerated. We
believe this is due in part to the excellent feedback we`ve received from our
customers which has guided our development efforts to improve the utility of
this productivity tool."

About Simulations Plus, Inc.

Simulations Plus, Inc., is a premier developer of groundbreaking drug discovery
and development simulation and modeling software, which is licensed to and used
in the conduct of drug research by major pharmaceutical and biotechnology
companies worldwide. The Company has two other businesses, Words+, Inc. and
FutureLab™, which are based on its proprietary software technologies.
Simulations Plus, Inc., is headquartered in Southern California. For more
information, visit our web site at www.simulations-plus.com.

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995
- With the exception of historical information, the matters discussed in this
press release are forward-looking statements that involve a number of risks and
uncertainties. The actual future results of the Company could differ
significantly from those statements. Factors that could cause or contribute to
such differences include, but are not limited to: continued acceptance and
licensing of DDDPlus and the other products of the Company, the ability of the
Company to maintain its competitive advantage, the general economics of the
pharmaceutical and assistive technology industries, the ability of the Company
to attract and retain sufficient scientific and technical staff to sustain its
R&D and customer support functions, the continued high renewal rate for the
Company`s software licenses, and a sustainable market. Further information on
the Company`s risk factors is contained in the Company`s quarterly and annual
reports as filed with the Securities and Exchange Commission.

Simulations Plus, Inc.
Investor Relations
Ms. Renée Bouché
661.723.7723
info@simulations-plus.com

Copyright Business Wire 2009